Charles River Laboratories International, Inc. (CRL)
NYSE: CRL · Real-Time Price · USD
210.48
-1.20 (-0.57%)
Jan 30, 2026, 4:00 PM EST - Market closed
CRL Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 27, 2025 | Dec '24 Dec 28, 2024 | Dec '23 Dec 30, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 25, 2021 | Dec '20 Dec 26, 2020 |
| 4,024 | 4,050 | 4,129 | 3,976 | 3,540 | 2,924 | |
Revenue Growth (YoY) | -0.92% | -1.92% | 3.86% | 12.31% | 21.07% | 11.55% |
Cost of Revenue | 2,628 | 2,642 | 2,600 | 2,508 | 2,203 | 1,850 |
Gross Profit | 1,395 | 1,408 | 1,529 | 1,468 | 1,337 | 1,074 |
Selling, General & Admin | 729.02 | 723.62 | 739.95 | 655.58 | 578.23 | 522.59 |
Amortization of Goodwill & Intangibles | 128.28 | 138.47 | 137.44 | 146.58 | 124.86 | 111.88 |
Operating Expenses | 857.3 | 862.09 | 877.39 | 802.15 | 703.08 | 634.47 |
Operating Income | 538.15 | 545.86 | 651.79 | 665.51 | 634.39 | 439.08 |
Interest Expense | -111.49 | -126.29 | -136.71 | -59.29 | -73.91 | -86.43 |
Interest & Investment Income | 5.76 | 8.58 | 5.2 | 0.78 | 0.65 | 0.83 |
Earnings From Equity Investments | -31.61 | -12.91 | 97.83 | -26.78 | -30.42 | 100.86 |
Currency Exchange Gain (Loss) | - | - | - | -46.53 | -31.83 | - |
Other Non Operating Income (Expenses) | -20.14 | 2.03 | -96.68 | -18.4 | 7.79 | 13.09 |
EBT Excluding Unusual Items | 380.68 | 417.26 | 521.43 | 515.3 | 506.67 | 467.43 |
Merger & Restructuring Charges | -116.21 | -108.49 | -37.68 | -15.71 | -45.96 | -10.01 |
Impairment of Goodwill | -215 | -215 | - | - | - | - |
Gain (Loss) on Sale of Assets | -0.66 | -0.66 | -0.96 | 123.41 | 20 | - |
Other Unusual Items | - | - | 98.5 | - | - | -10.3 |
Pretax Income | -22.2 | 93.11 | 581.28 | 622.99 | 480.71 | 447.11 |
Income Tax Expense | 57.43 | 67.82 | 100.91 | 130.38 | 81.87 | 81.81 |
Earnings From Continuing Operations | -79.62 | 25.29 | 480.37 | 492.61 | 398.84 | 365.31 |
Net Income to Company | -79.62 | 25.29 | 480.37 | 492.61 | 398.84 | 365.31 |
Minority Interest in Earnings | -2.66 | -3.09 | -5.75 | -6.38 | -7.86 | -1 |
Net Income | -82.28 | 22.2 | 474.62 | 486.23 | 390.98 | 364.3 |
Preferred Dividends & Other Adjustments | 1.2 | 11.91 | - | - | - | - |
Net Income to Common | -83.48 | 10.3 | 474.62 | 486.23 | 390.98 | 364.3 |
Net Income Growth | - | -95.32% | -2.39% | 24.36% | 7.32% | 44.55% |
Shares Outstanding (Basic) | 50 | 51 | 51 | 51 | 50 | 50 |
Shares Outstanding (Diluted) | 50 | 52 | 51 | 51 | 51 | 51 |
Shares Change (YoY) | -3.04% | 0.34% | 0.29% | -0.24% | 1.61% | 1.85% |
EPS (Basic) | -1.67 | 0.20 | 9.27 | 9.57 | 7.77 | 7.35 |
EPS (Diluted) | -1.67 | 0.20 | 9.22 | 9.48 | 7.60 | 7.20 |
EPS Growth | - | -97.83% | -2.74% | 24.74% | 5.56% | 42.01% |
Free Cash Flow | 543.67 | 501.61 | 365.37 | 294.91 | 532.03 | 380.02 |
Free Cash Flow Per Share | 10.86 | 9.72 | 7.10 | 5.75 | 10.35 | 7.51 |
Gross Margin | 34.68% | 34.76% | 37.03% | 36.91% | 37.78% | 36.72% |
Operating Margin | 13.38% | 13.48% | 15.78% | 16.74% | 17.92% | 15.02% |
Profit Margin | -2.08% | 0.25% | 11.49% | 12.23% | 11.04% | 12.46% |
Free Cash Flow Margin | 13.51% | 12.38% | 8.85% | 7.42% | 15.03% | 13.00% |
EBITDA | 884.89 | 898.2 | 965.92 | 969.38 | 899.93 | 674 |
EBITDA Margin | 21.99% | 22.18% | 23.39% | 24.38% | 25.42% | 23.05% |
D&A For EBITDA | 346.74 | 352.34 | 314.12 | 303.87 | 265.54 | 234.92 |
EBIT | 538.15 | 545.86 | 651.79 | 665.51 | 634.39 | 439.08 |
EBIT Margin | 13.38% | 13.48% | 15.78% | 16.74% | 17.92% | 15.02% |
Effective Tax Rate | - | 72.84% | 17.36% | 20.93% | 17.03% | 18.30% |
Revenue as Reported | 4,024 | 4,050 | 4,129 | 3,976 | 3,540 | 2,924 |
Updated Nov 5, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.